Bronchial Thermoplasty in Asthma  by Mitzner, Wayne
Bronchial Thermoplasty in Asthma
Wayne Mitzner1
ABSTRACT
In this review we discuss the potential of a new procedure, termed Bronchial Thermoplasty to prevent serious
consequences resulting from excessive airway narrowing. The most important factor in minimizing an asth-
matic attack is limiting the degree of smooth muscle shortening. The premise that airway smooth muscle can
be either inactivated or obliterated without any long-term alteration of other lung tissues, and that airway func-
tion will remain normal, albeit with reduced bronchoconstriction, has now been demonstrated in dogs, a subset
of normal subjects, and mild asthmatics. Bronchial Thermoplasty may thus develop into a useful clinical proce-
dure to effectively impair the ability for airway smooth muscle to reach the levels of pathologic narrowing that
characterizes an asthma attack. It may also enable more successful treatment of asthma patients who are un-
responsive to more conventional therapies. Whether this will remain stable for the lifetime of the patient still re-
mains to be determined, but at the present time, there are no indications that the smooth muscle contractility
will return. This successful preliminary experience showing that Bronchial Thermoplasty could be safely per-
formed in patients with asthma has led to an ongoing clinical trial at a number of sites in Europe and North
America designed to examine the effectiveness of this procedure in subjects with moderately severe asthma.
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INTRODUCTION
Asthma is an often debilitating disease characterized
by dyspnea , wheezing , coughing , respiratory dis-
tress , and sometimes death . Subjects with asthma
typically have hyperresponsive and often chronically
inflamed airways. Chronic asthma is also character-
ized by extensive airway remodeling,1 with a thicken-
ing of airway walls, increased mucus glands and gob-
let cells, increased vascularization, and most impor-
tantly , hypertrophy of airway smooth muscle . Al-
though there are many different opinions on the
causes and mechanisms involved in asthma, there is
universal agreement that airways narrow during an
asthmatic attack. It is from this perspective that we
will begin this review of a procedure, termed Bron-
chial Thermoplasty, in asthma.
Once we agree that the problem in asthma is
caused by airway narrowing, then it is reasonable to
ask what the cause of this airway narrowing might
be. There are several possibilities . One is that the
fluid that lines the airway becomes thicker . This
could occur because of increased mucus secretion,
something that is known to occur in many individuals
with asthma,2 and is often observed pathologically in
subjects who have died from a severe attack. 3,4 In-
deed, sometimes in these post-mortem cases, the se-
cretions are sufficient to completely fill parts of the
airway tree. In this review, we will not have more to
say about this potential cause of airway narrowing,
not because it is unimportant, but rather because its
extent and manifestation in the general population of
asthmatic subjects is not well characterized.
Another possible mechanism of airway narrowing
is loss of mechanical support from the surrounding
parenchyma. It is now well understood that within the
lung airways are tethered by attachments to the pa-
renchyma, and loss of this support leads to airway
narrowing. Although this is a serious problem in em-
physema, there is little evidence that the airway nar-
rowing in asthma is caused by loss of parenchymal
support . Related to this potential loss of structural
tethering is the effect of lung volume and elastic re-
coil on airway size. Airways would be smaller at lower
lung volume, but in asthma, lung volumes are gener-
ally increased. There has also been some evidence of
altered surfactant in asthma,5 although it is not clear
how an increased surface tension in the alveoli would
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act on airway size. The effect would depend on the
relative changes in lung volume and elastic recoil
pressure , but one recent report did show a slight
positive effect of synthetic surfactant in asthmatic
subjects.6
The third possible cause of airway narrowing, that
of airway smooth muscle contraction, is the one that
will be the focus of the remainder of this review. All
of the conducting airways down to the level of respi-
ratory bronchioles are lined with smooth muscle .
This smooth muscle has a great capacity to shorten.
Indeed, all airways in the lung (including large carti-
laginous ones) can narrow to complete closure if the
airway smooth muscle is stimulated sufficiently . 7
Smooth muscle shortening is considered to be the
primary cause of the difficulties in breathing during
an acute asthma attack. Narrowed airways require in-
creased transpulmonary pressure and energy expen-
diture during inspiration, and during expiration are
much more likely to reach flow limitation at low lung
volumes. It is for this reason, that all of the therapeu-
tic research related to asthma has focused on mini-
mizing the ability of the airway smooth muscle to
shorten.
THERAPEUTIC APPROACHES
Acute relaxation of the airway contractile response
can be accomplished with cholinergic blockade, but
in recent decades it has been achieved primarily with
β-adrenergic stimulation. Either of these stimulations
will lead to bronchodilation. Another more common
contemporary approach in patients with moderate
and severe asthma has involved anti-inflammatory
agents, either alone or with short or long-acting β-
adrenergic agonists . 8 This combined use of anti-
inflammatory agents with inhaled bronchodilators is
a successful therapy for control of asthma in many pa-
tients. Furthermore, in the very recent past, a num-
ber of newer inhibitors of inflammatory pathways
have been available for those patients who do not re-
spond well to the conventional therapy.9-11 Neverthe-
less, despite this attempt to control the inflammatory
pathways in asthma, serious exacerbations still often
occur in patients with even mild asthma,12 and some
patients with severe asthma are poorly responsive to
all forms of therapy. Indeed mortality from asthma
has remained fairly steady for the past 15 years . 13
Thus it is clear the there is still much to be learned
about this pathology. Despite much experimental evi-
dence linking inflammation to airway smooth muscle
shortening , the detailed mechanistic pathways re-
main elusive. There exists a very poor understanding
of why conventional therapy works well in some pa-
tients but manifests such poor pharmacological re-
sponsiveness in others. While it has been suggested
that a poor responsiveness to drug therapy in asthma
is genetically determined,14 this hasn’t helped in clari-
fying the mechanisms, nor helped in providing better
therapy. Furthermore, while it is true that increasing
knowledge of immunological pathways may lead to
therapeutic value in asthma, the fact remains that an
asthma attack can often be triggered by non-allergic
stimuli, such as infection, exercise, or cold air. Thus
we always return to the fact that whether the initial
cause results from an allergen, an irritant, infection,
psychological stress, or other neural activation, the
cascade during an attack always ends with airway
muscle contraction.
This lack of success in pharmacologically treating
asthmatic airways has led to a recent proposal that
takes a very different approach. If the smooth narrow-
ing is the problem, then why not try to physically im-
pair the ability of this smooth muscle to shorten? Ig-
noring for the moment the potential difficulty in do-
ing this, it seems clear that, in the extreme, if the
smooth muscle were completely eliminated , then
there could be no acute airway narrowing. Thus, if we
could eliminate airway smooth muscle, then perhaps
we would a permanent cure for asthma. Of course
this potential raises the issue of whether the airway
smooth muscle has any normal functions, and this
will be discussed in subsequent section.
In this review, we will describe a method that is
now undergoing limited clinical trials in the U.S . ,
whereby locally applied thermal energy is used to
damage the smooth muscle of conducting airways
sufficiently to impair their ability to narrow. The gen-
eral hypothesis underlying this clinical trial is that
even partially impairing the ability of the conducting
airways to narrow will not only attenuate the bron-
choconstrictor response, but will also be effective in
relieving the dyspnea associated with asthmatic at-
tacks. In subsequent sections, we will present experi-
mental evidence in a canine model and preliminary
studies in human subjects that was used to justify the
current clinical trial.
ROLE OF SMOOTH MUSCLE IN ASTHMA
With the understanding that airway smooth muscle
holds the key to dealing with the asthma pathology,
we next address several relevant issues.
WHICH AIRWAYS CAUSE THE PROBLEM IN
ASTHMA？
One important question in asthma is which genera-
tion of airways contributes most to airflow obstruc-
tion during an asthma attack. This is a critical issue
that bears on the whole approach of Bronchial Ther-
moplasty, since as will be described later, the current
technique cannot treat airways smaller than about 3
mm diameter. However, after many years of debate
on whether large or small airways are more responsi-
ble for airflow obstruction during asthma attacks ,
there remains little experimental evidence on which
to base any conclusive answer. It is well accepted and
known from morphometric models of Weibel,15 Hors-
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field,16,17 and others,18 that nearly all of the baseline
airway resistance lies in the conducting airways >2
mm. With smooth muscle contraction this partition-
ing can surely change, but this situation has not been
extensively modeled. Indeed, for many years it was
thought that the cartilagenous structure of large air-
ways was such that it might limit their ability to con-
strict as much as the smaller ones. However, a study
using CT imaging of airways7 showed that even large
cartilaginous airways could narrow to complete clo-
sure if sufficiently stimulated, thereby dispelling that
myth. Such large airway closure was also reported in
human subjects.19 Thus, the locus of airway constric-
tion during an acute asthma attack is still not fully
elucidated. Is it a global narrowing of small airways,
an acute narrowing of a few large airways, or a gener-
alized narrowing of all airways in the entire bronchial
tree? Lacking any convincing experimental evidence
to the contrary, one can assume the simplest explana-
tion, which is that it is a generalized narrowing of all
airways. Since, as mentioned, most of the airway re-
sistance at baseline lies in the larger airways , an
equivalent degree of narrowing throughout the air-
way tree will have its greatest impact on resistance in
these larger airways. Furthermore, a recent theoreti-
cal analysis of constriction in the three dimensional
airway tree has shown how it is possible for large air-
way narrowing to directly affect narrowing in small
airways.20 For these reason, it is reasonable to expect
that impairment of the ability of the conducting air-
ways to narrow could have a substantial beneficial ef-
fect on the ability to breath during an asthma attack.
IS AIRWAY SMOOTH MUSCLE DIFFERENT IN
ATHMATICS？
The fact that airways of asthmatic subjects narrow
more than normal subjects is axiomatic. The cause of
this excessive narrowing, however, remains unclear.
There are structural, chemical, and physiological rea-
sons why airways in this pathology might narrow ex-
cessively. There may be more smooth muscle in the
wall,21 the wall may be thicker causing the narrowing
to start from a smaller baseline size [which would am-
plify the effect of any further muscle shortening],22-24
the elasticity of the wall and surrounding parenchyma
may be reduced, the smooth muscle may have intrin-
sic differences in contractility, there may be more re-
ceptors on the muscle for agonist stimulation, the in-
tracellular signaling pathways may be upregulated, or
extracellular signals for smooth muscle contraction
may become elevated.25 Although much research has
been directed toward investigating these different fac-
tors , how these all integrate in an intact lung be-
comes less important if the smooth muscle cannot
contract or is eliminated.
WHAT IS THE FUNCTION OF AIRWAY SMOOTH
MUSCLE？
The human body contains many organs, which no
longer provide evolutionary advantage and have no
known function, e.g., the appendix, most body hair,
wisdom teeth, male nipples, and external ear mus-
cles . It recently has been argued 26 that airway
smooth muscle falls into this category―that of an or-
gan with no known physiologic purpose, whose sole
contemporary contribution is the potential to cause
problems. This argument supports an earlier discus-
sion by Seow and Fredberg,27 who emphasized that
there is no known disease entity or physiological defi-
cit associated with loss of airway smooth muscle .
They further suggested that airway smooth muscle
was perhaps a vestigial remnant of its common em-
bryologic origin with the GI system. So from where
does the widespread feeling, that airway smooth mus-
cle must have some function , arise ? Some of this
background is summarized below.
Despite that fact that the function of smooth mus-
cle in the airway wall has been speculated on for
many years, from a functional perspective, there has
never been strong experimental evidence for its func-
tional importance in the lung. Not withstanding this
lack of experimental evidence, Macklin,28 in his clas-
sic extensive and influential review article on airway
smooth muscle, could not imagine that such a system
existed for no physiologic purpose, stating, “Organ-
ized as it is, into a very complex system, this muscle
would seem of the utmost functional importance―in
fact quite indispensable in respiration.”
At least 10 postulated roles for airway smooth mus-
cle have appeared in the literature . These possible
roles consist of the following: 1. Peristalsis to assist
exhalation; 2. Peristalsis to assist mucus propulsion;
3. Peristaltic contraction in the fetal lung to generate
fluid pressure ; 4. Promoting lymphatic and venous
flow; 5.VentilationPerfusion matching; 6. Protecting
the peripheral lung; 7. Protecting airway structure; 8.
Stabilizing airways; 9. Enhancing the effectiveness of
cough; and 10. Optimizing anatomic dead space vol-
ume. Details of each of these have been presented
elsewhere26 and will not be repeated here. However,
it should be noted that none of these potential func-
tions of airway smooth muscle have been shown to
be essential to normal lung physiology . If airway
smooth muscle were eliminated , then the airways
might enlarge slightly due to loss of basal tone, but
there would be no other obvious physiologic conse-
quence. The evidence thus strongly supports the sug-
gestion that airway smooth muscle is indeed like a
vestigial organ,26 analogous to the appendix, which
also has no known purpose other than to cause seri-
ous medical problems. Such being the case, if there
were a way to treat airway smooth like an inflamed
appendix, that is, to effectively cut it out, then asthma,
like appendicitis, could be cured. Airway inflamma-
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Fig. 1 Schematic ilustration of the instrument used to per
form radiofrequency alteration of airway smooth muscle re
sponsiveness in dogs and humans. The catheter conducts 
RF energy to the airway by direct contact to heat the airway 
wal. The bronchoscope is directed to the area, the basket is 
then expanded, and RF heat treatment is activated for very 
short duration, typicaly 10 s. The basket is then withdrawn 
and the instrument is directed to the next site. (Alair® device 
developed by Asthmatx, Inc.).
Fig. 2 Efect of Bronchial Thermoplasty treatment in vivo 
in a canine airway. The airway on the left received treat
ment, but did not constrict by local administration of Mch 
through the bronchoscope. By contrast, the untreated air
way on the right (arow) constricts nearly to closure with the 
same stimulus.
tion may still be present , but without an ability to
translate inflammatory signals into airway smooth
muscle contraction, severe dyspnea and ventilatory
impairment from airway closure and respiratory mus-
cle fatigue would be greatly minimized.
BRONCHIAL THERMOPLASTY METHODOL-
OGY
Bronchial Thermoplasty is performed using the
AlairⓇ System from Asthmatx, Inc., Mountain View,
CA, USA. This system has been used safely in ani-
mals , 29 and non-asthmatic 30 and asthmatic human
subjects.31,32
Airways to be treated are approached through a
bronchoscope, and an expandable basket with four
electrode arms is opened to make contact with the
airway wall circumferentially . This is illustrated in
Figure 1. Treatment generally causes an acute
blanching at the site of treatment , and histology
shows epithelial disruption at treated sites. There is
no charring of the treated area, and subsequent re-
growth occurs in the epithelium, blood vessels, mu-
cosa, and nerves. Airway smooth muscle, however,
seems to have almost no capacity for regeneration.
The airway smooth muscle at is replaced by loose
connective tissue. Studies have been performed in
dogs to determine the optimal temperature and treat-
ment times 29 to effect selective ablation of airway
smooth muscle without causing long-term damage to
other tissues. Initial studies mapped different sites in
the airways of the same dogs so that these sites could
be revisited for visual and, eventually, histological ex-
amination. The major variables at each site were tem-
perature and duration of treatment. In this first study
airway caliber was measured with a semiquantitative
optical system, but subsequent studies using high
resolution CT provided more accurate quantification
of airway responsiveness. Figure 2 shows optical im-
ages taken through a bronchoscope of locally applied
methacholine (Mch) to a treated and untreated air-
way. The lack of responsiveness in the treated airway
is readily apparent.
ANIMAL VALIDATION AND EXPERIMANTAL
RESULTS
Danek et al.29 studied the clinical manifestation and
long term effects of Bronchial Thermoplasty on ca-
nine airways . Dogs tolerated the treatment well .
There were no adverse physiological or clinical ob-
servations made during the 3-year study. With direct
visualization through a bronchoscope, they recorded
the ability of treated and untreated airways to re-
spond to topically applied Mch . They followed a
group of dogs for up to 3 years following treatment. A
summary of their findings is shown in Figure 3.
These results clearly show a substantial and pro-
longed attenuation of airway constriction to locally ap-
plied Mch. Gross histology showed no gross narrow-
ing of airways , generalized fibrosis beyond the
boundaries of the smooth muscle, or retained mucus
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Fig. 3 Mean airway responsiveness ploted as the fractional change in diameter folowing 
local Mch chalenge in airways subjected to Bronchial Thermoplasty at 75℃. Control airways 
show a stable response to Mch over the course of the 3-year study. Treated airways show a 
statisticaly significant reduction in response to Mch at al post-treatment folow-up times (p＜＿ 
0.001).
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Fig. 4 Inverse corelation between airway responsiveness ploted as the percent change in air-
way diameter folowing local Mch chalenge vs. the percentage of airway circumference contain-
ing altered airway smooth muscle. Data shown are mean values for each histological time point.
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in the airways. As shown in Figure 4, the degree of at-
tenuation of the contractile response to Mch was also
shown to correlate well to the degree of smooth mus-
cle loss . Similar treatment parameters determined
from studies in dogs are now being used for prelimi-
nary trials in the conducting airways of the human
lung (see next section). After treatment, some degree
of airway responsiveness to locally applied Mch still
remains in airways in dogs in which smooth muscle
appears to be replaced by loose connective tissue. As
the treatment effect is localized to the site of treat-
ment, smooth muscle between treatment sites may
be less affected, the muscle being sufficiently con-
tractile to cause some airway narrowing upon chal-
lenge. These results further support the conjecture
that with the current treatment paradigm, the muscle
at treatment sites is not fully ablated. While it might
be desirable to cause greater impairment of smooth
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Fig. 5 Airway size (mean±sem) at baseline and with increasing concentrations of aerosolized Mch in the 
treated (circles) and untreated (squares) airway groups. Results are shown for pretreatment and 4 weeks 
post-treatment. There were no significant diferences in airway size either at baseline or at any Mch dose be-
tween the two groups at pretreatment time. At 4 weeks post-treatment there were significant increases (p＜
0.01) in the size of treated airways at al Mch doses above 0.3 mg/ml compared to the untreated airways.
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muscle, the current protocol is designed to empha-
size safety (perhaps at the expense of efficacy) for the
early human trials . Another potential concern with
extrapolation to humans is the potential for damage
to the airway to develop over time, perhaps as a result
of progressive injury and fibrosis. However in this ca-
nine study there were no functional or clinical ad-
verse outcomes over 3 yrs following treatment.
In this initial evaluation of this potential therapy in
a canine model, Danek et al. 29 described airway re-
sponsiveness to local Mch challenge by visually esti-
mating airway diameters . In a subsequent study ,
high-resolution computed tomography (HRCT) was
used to more accurately quantify the changes in air-
way area before and to obtain the full Mch dose-
response curve in airways treated with Bronchial
Thermoplasty.33 Dose-response curves in untreated
and treated airways 4 weeks after treatment are sum-
marized in Figure 5. These results show that Bron-
chial Thermoplasty can significantly attenuate the
ability of airways to narrow in response to Mch―the
airway size of treated airways was larger at baseline
and at all doses of Mch. This increase was substan-
tial , being greater than 50% at the higher doses of
Mch. Although we did not follow the animals beyond
one month in this more quantitative study, in the pre-
vious work by Danek et al., dogs with a similar treat-
ment were shown to maintain this impaired ability to
narrow for at least 3 years following treatment.
It may also be important that we found the treated
airways larger than untreated airways even prior to
Mch challenge. One possibility to account for this
might involve structural alterations to other (nonmus-
cle) components in the airways, such as collagen or
other fibrous elements. Damage to these fixed struc-
tures in the airway wall from the Bronchial Thermo-
plasty could contribute to a slight dilation of the air-
ways even without a reduction in baseline airway
smooth muscle tone. However, such changes are not
consistent with the results of Danek et al. that
showed no significant histologic changes to the air-
ways other than to the smooth muscle after a similar
Bronchial Thermoplasty in dogs . 29 A more likely
cause of the slight dilation of the airways prior to
Mch relates to the loss of baseline tone. There is nor-
mally a variable amount of baseline tone, which is de-
pendent on variable amounts of smooth muscle acti-
vation.34 This fact may explain why there was also a
slightly larger airway size at baseline in the untreated
airways at the selected time points. However, if the
muscle is reduced or impaired by Bronchial Thermo-
plasty, then not only would the ability to respond to
Mch be impaired, but the normal baseline tone would
also be expected to decrease.
Using HRCT imaging we also measured effect of
Bronchial Thermoplasty on the distensibility of
treated airways.35 Figure 6 summarizes the effect 5
weeks following treatment. The figure shows airway
pressure-area relations in two groups of airways prior
to treatment and then at 5 weeks following treatment
in one group. Airway areas were measured at increas-
ing levels of end expiratory pressure curves, and Fig-
ure 6 shows the results with no smooth muscle tone.
The curves show that even in relaxed airways, the
size is increased at all levels of inflation. This increase
at baseline (no tone), however, is relatively small, be-
ing between 10 and 15% at the higher levels of pres-
sure . Such slight baseline increases in airway size
would likely be difficult to detect clinically using
gross pulmonary function measures, such as FEV1.
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Fig. 6 Airway size (mean±sem) at baseline and at increasing airway pressure after atropine in the subse-
quently treated (circles) and untreated (squares) airways. Results are shown for pretreatment and 5 weeks post-
treatment. There were no significant diferences in the airway size either at baseline or after any of the airway 
pressures between the two groups at pretreatment. At 5 weeks post-treatment there were highly significant difer-
ences (p＜0.0001) in the size of treated airways during Mch infusion compared to untreated airways.
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And as will be shown in the next section, this predic-
tion is what was observed in the preliminary human
trial. In this same canine study,35 we also measured
the distensibility with a moderate level of airway con-
traction with Mch. In this situation, the cross sec-
tional area of treated airways was more than doubled
that of untreated airways at all but the highest pres-
sure , a result consistent with the dose-response
curves shown in Figure 5.
PRELIMINARY HUMAN DATA
The first studies using Bronchial Thermoplasty were
carried out in nonasthmatic subjects who were sched-
uled to undergo pulmonary resection for suspected
neoplasm.30 Those subjects scheduled to have a bron-
choscopy for preoperative evaluation 1―3 weeks prior
to surgery lung resection for suspected or proven
lung cancer were enrolled. This provided the oppor-
tunity to carry out the procedure in airways that
would be available for histological examination soon
thereafter. Thus, while this first study did provide any
assessment of lung function, it did provide an ideal
opportunity to evaluate whether the acute pathologic
response of human airways was similar to that ob-
served in canine airways.29 Specifically, this study de-
sign enabled determination of the safety of the Bron-
chial Thermoplasty in humans over the short term,
examination of the histologic effects of the procedure
in the human airway, and comparison of the extent of
airway smooth muscle loss to that observed in the ca-
nine model . As bronchoscopy was repeated at the
time of surgery, there was also opportunity to inspect
the bronchial lining at the sites of treatment to evalu-
ate possible in vivo consequences.
The nine subjects treated in this study had no ad-
verse events related to the procedure, and there were
no interruptions or delays to the planned manage-
ment of their primary clinical problem. Treated sites
exhibited slight redness and edema of the mucosa
within 2 weeks of treatment, and appeared normal at
later time points. There was some narrowing in four
individual airways in two subjects examined at 5 days
and 13 days after treatment, with excess mucus in
two of these airways. There was no bronchoscopic
evidence of scarring in any of the airways examined.
Histologic examination showed a reduction in airway
smooth muscle, and the extent of the treatment effect
was confined to the airway wall and the immediate
peribronchial region, as was expected from observa-
tions in the canine model. This study thus showed
that application of Bronchial Thermoplasty to the hu-
man airway was well tolerated, leading to a significant
reduction of smooth muscle mass in the airways.
A longer term evaluation was more recently re-
ported in 16 asthmatic subjects.32 These 16 adult sub-
jects with mild or moderate asthma were followed for
12 months without any evidence of chronic or pro-
gressive airway injury. The procedure treated all ac-
cessible airways greater than 3 mm in the lower and
upper lobes. This was accomplished in 3 broncho-
scopy sessions, each at least 3 weeks apart. All sub-
jects tolerated the procedure well and were dis-
charged at the end of a 6-hour observation period for
each treatment session. In the days after treatment
there was an increase in the frequency of airway
symptoms , such as cough , mucous production ,
hoarseness and dyspnea . Examination of daily re-
cords of peak flows showed modest reduction sug-
gesting that the symptoms were primarily those of
bronchial irritation rather than airflow obstruction .
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Fig. 7 Prebronchodilator FEV1, ploted as % of baseline for individual subjects over 
the 2-year study period.
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Fig. 8 Individual and mean Mch PC20 values at baseline, 
12 weeks, 1 year, and 2 years after Bronchial Thermoplasty.
Mean
100.00
10.00
1.00
0.10
0.01
Baseline 12 Weeks 1 Year 2 Years
Time
M
ch
 P
C
20
 (
m
g/
m
l)
The symptoms experienced by the subjects in this
trial after Bronchial Thermoplasty were similar to
those experienced by other subjects with asthma un-
dergoing bronchoscopy and related procedures . 36
Subjects were followed for 2 years following treat-
ment . Results showed the following significant
changes in FEV1, symptom free days, and airway re-
sponsiveness to Mch challenge.
FEV1: Bronchial Thermoplasty had no significant
effect on % predicted FEV1 at 2 years following treat-
ment. The time course of FEV1 changes is shown in
Figure 7. Curiously there were significant increases
in FEV1 observed at 12 weeks (p = 0.043) and 1 year
(p = 0.030). Post-bronchodilator FEV1 showed no sig-
nificant change from baseline throughout the time pe-
riod. As mentioned earlier, this slight and inconsis-
tent behavior of FEV1 after treatment is what might
be expected based on the slight increases in airway
area observed in dogs after treatment. The inconsis-
tency may also reflect varying degrees of baseline air-
way tone.
Symptom-Free Days. There was a highly signifi-
cant (P = 0.015) increase in the mean percentage of
symptom-free days from 50% pretreatment to 73% 12
weeks after treatment. During this 12-week follow-up
period, almost 34 of the subjects experienced an in-
crease in percentage of symptom-free days. This ob-
servation likely reflects the fact that the ability for air-
ways to narrow has been greatly impaired . This
speculation is supported by the results measuring the
response to Mch challenge.
Airway responsiveness to Mch. After Bronchial
Thermoplasty , the geometric mean PC20 increased
from 0.92 mgml to 4.75 at 12 weeks, 5.45 at 1 year
and 3.40 at 2 years. Individual data contributing to
these means are shown in Figure 8. It is important to
that these means may underestimate the actual ef-
fect. This is because several subjects did not experi-
ence a 20% drop in FEV1 even with the highest con-
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centration of Mch allowed by the protocol. This dose
was 16 mgml, and so these subjects were attributed
a value of 16. Had it been possible to measure, their
actual PC20’s would have been greater , and this
would have increased the means. But even with this
conservative limitation, the improvements observed
throughout the study period represented approxi-
mately 2.4 doublings at 12 weeks, 3.0 doublings at 12
months and 2.3 doublings at 1 year.
This preliminary study thus confirms what was ob-
served in the canine model. There was a clinically sig-
nificant decrease in airway responsiveness following
Bronchial Thermoplasty that persisted for at least 2
years after treatment. And since hyperresponsive air-
ways are perhaps the most important functional com-
ponent of asthma, it likely that this finding was a di-
rect cause of the increase in symptom free days.37
Finally , we note that , although this preliminary
clinical study was designed primarily to evaluate the
feasibility and safety of Bronchial Thermoplasty, the
results revealed several functional and practical clini-
cal improvements. It is worth emphasizing again the
potential lack of relevance of FEV1, despite its com-
mon use as a clinical endpoint in pharmacologic stud-
ies . This lack of change in FEV1 may superficially
suggest that there is minimal beneficial effect of
Bronchial Thermoplasty. FEV1 is a complex variable
that depends on both airway resistance and lung
elastance, and is preceded by a very large lung infla-
tion. The effect of this inflation itself has been shown
to have variable effects on airways of normal and
asthmatic subjects,38-40 with normal subjects showing
airway dilation following deep inspiration and asth-
matic subjects often showing no change or even a fur-
ther constriction. The effect of a deep inspiration on
airways treated with Bronchial Thermoplasty in hu-
mans is unknown at this time. However, if the treat-
ment does in fact make asthmatic airways more like
those in normal subjects, then the effect of the pre-
ceding deep inspiration would be to result in a de-
creased airway resistance and higher FEV1. This is
pure speculation at this time, but the preliminary data
from human subjects is consistent with this conjec-
ture.
SUMMARY
In summary, we have discussed the potential of Bron-
chial Thermoplasty to prevent serious consequences
resulting from excessive airway narrowing. The most
important factor in minimizing an asthmatic attack is
limiting the degree of smooth muscle shortening .
The premise that airway smooth muscle can be either
inactivated or obliterated without any long-term al-
teration of other lung tissues, and that airway func-
tion will remain normal , albeit with reduced bron-
choconstriction, has now been demonstrated in dogs
and a subset of normal subjects and mild asthmatics.
Bronchial Thermoplasty may thus develop into a use-
ful clinical procedure to effectively impair the ability
for airway smooth muscle to reach the levels of pa-
thologic narrowing that characterizes an asthma at-
tack. It may also enable more successful treatment of
asthma patients who are unresponsive to more con-
ventional therapies. Whether this will remain stable
for the lifetime of the patient still remains to be deter-
mined, but at the present time, there are no indica-
tions that the smooth muscle contractility will return.
This successful preliminary experience showing that
Bronchial Thermoplasty could be safely performed in
patients with asthma has led to an ongoing clinical
trial at a number of sites in Europe and North Amer-
ica designed to examine the effectiveness of this pro-
cedure in subjects with moderately severe asthma.
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